scholarly journals Relationship between serum testosterone and nocturia in men without benign prostate enlargement

Andrology ◽  
2016 ◽  
Vol 5 (1) ◽  
pp. 58-62 ◽  
Author(s):  
S. U. Jeh ◽  
S. Yoon ◽  
D. H. Seo ◽  
S. W. Lee ◽  
C. Lee ◽  
...  
Keyword(s):  
Serum Testosterone ◽  
Prostate Enlargement ◽  
Benign Prostate

scholarly journals MP35-08 RELATIONSHIP BETWEEN SERUM TESTOSTERONE AND NOCTURIA IN MEN WITHOUT BENIGN PROSTATE ENLARGEMENT

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Seong Uk Jeh ◽  
Sol Yoon ◽  
Deok Ha Seo ◽  
See Min Choi ◽  
Sung Chul Kam ◽  
...  
Keyword(s):  
Serum Testosterone ◽  
Prostate Enlargement ◽  
Benign Prostate

scholarly journals Relationship between Serum Testosterone and Nocturia in Men without Benign Prostate Enlargement

2016 ◽  
Vol 9 (1) ◽  
pp. 167-167
Author(s):  
S. Jeh ◽  
◽  
D. Seo ◽  
S. Choi ◽  
S. Kam ◽  
...  
Keyword(s):  
Flow Rate ◽  
Testosterone Level ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Multivariate Logistic Regression Analysis ◽  
Serum Testosterone ◽  
Total Testosterone ◽  
Urinary Flow ◽  
Prostate Enlargement ◽  
Benign Prostate

Objective: To clarify the relationship between serum total testosterone and nocturia in males without an enlarged prostate. Design and Method: Among the 1029 male patients who visited our clinic for health screening from January 2010 to July 2014, 596 patients without benign prostate enlargement (BPE) were analyzed. To evaluate the effect of serum total testosterone on prevalence of nocturia and number of nocturia episodes, multivariate analyses were performed including the covariates of age, International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) score, body mass index, prostate specific antigen, prostate volume and maximal urinary flow rate. Results: Mean prostate volume was 21.70±4.34 ml and prevalence of nocturia (over 1 times/night) was 22.1%. Multivariate logistic regression analysis revealed positive associations of age (OR 1.048, P = 0.005), total IPSS (OR 1.217, P <0.001) and testosterone level (OR 1.115, P = 0.041) with the prevalence of nocturia. Although the mean testosterone level was progressively elevated as the number of nocturia episodes increased, no consistent association with the number of nocturia episodes was seen for testosterone after adjusting for age, IPSS, IIEF score and maximal urine flow rate. Conclusions: Serum total testosterone level is significantly positively associated with the prevalence of nocturia. Therefore, in men without enlarged prostate, testosterone seems to have an opposing role in the etiology of nocturia.

scholarly journals Bipolar Endoscopic Enucleation of Big Benign Prostate Enlargement

Prostatectomy ◽  
2019 ◽  
Author(s):  
Wai Hee Steve Chan ◽  
Chi Fai Kan ◽  
Churk Fai Trevor Li
Keyword(s):  
Prostate Enlargement ◽  
Endoscopic Enucleation ◽  
Benign Prostate

scholarly journals Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men

2015 ◽  
Vol 308 (12) ◽  
pp. E1035-E1042 ◽  
Author(s):  
Stephen E. Borst ◽  
Joshua F. Yarrow
Keyword(s):  
Meta Analysis ◽  
Serum Testosterone ◽  
Older Men ◽  
Testosterone Replacement Therapy ◽  
Mineral Density ◽  
Transdermal Administration ◽  
Prostate Enlargement ◽  
Accompanying Symptoms ◽  
Long Acting ◽  
Dose Dependent

The value of testosterone replacement therapy (TRT) for older men is currently a topic of intense debate. While US testosterone prescriptions have tripled in the past decade (9), debate continues over the risks and benefits of TRT. TRT is currently prescribed for older men with either low serum testosterone (T) or low T plus accompanying symptoms of hypogonadism. The normal range for serum testosterone is 300 to 1,000 ng/dl. Serum T ≤ 300 ng/dl is considered to be low, and T ≤ 250 is considered to be frank hypogonadism. Most experts support TRT for older men with frank hypogonadism and symptoms. Treatment for men who simply have low T remains somewhat controversial. TRT is most frequently administered by intramuscular (im) injection of long-acting T esters or transdermally via patch or gel preparations and infrequently via oral administration. TRT produces a number of established benefits in hypogonadal men, including increased muscle mass and strength, decreased fat mass, increased bone mineral density, and improved sexual function, and in some cases those benefits are dose dependent. For example, doses of TRT administered by im injection are typically higher than those administered transdermally, which results in greater musculoskeletal benefits. TRT also produces known risks including development of polycythemia (Hct >50) in 6% of those treated, decrease in HDL, breast tenderness and enlargement, prostate enlargement, increases in serum PSA, and prostate-related events and may cause suppression of the hypothalamic-pituitary-gonadal axis. Importantly, TRT does not increase the risk of prostate cancer. Putative risks include edema and worsening of sleep apnea. Several recent reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report no risk or even benefit. To address the potential CV risks of TRT, we have recently reported via meta-analysis that oral TRT increases CV risk and suggested that the CV risk profile for im TRT may be better than that for oral or transdermal TRT.

scholarly journals Aquablation: a novel and minimally invasive surgery for benign prostate enlargement

2018 ◽  
Vol 10 (6) ◽  
pp. 183-188 ◽  
Author(s):  
Samih Taktak ◽  
Patrick Jones ◽  
Ahsanul Haq ◽  
Bhavan Prasad Rai ◽  
Bhaskar K. Somani
Keyword(s):  
High Pressure ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Safety And Efficacy ◽  
Surgical Technology ◽  
Minimally Invasive Surgical ◽  
Early Results ◽  
Prostate Enlargement ◽  
Benign Prostate

Aquablation is a minimally invasive surgical technology for benign prostate enlargement, which uses high-pressure saline to remove parenchymal tissue through a heat-free mechanism of hydrodissection. Early results show this to be a promising surgical strategy with a strong morbidity profile and reduced resection time. This review serves to provide an overview of the technique and evaluate its safety and efficacy.

scholarly journals PREPARASI PEREAKSI KIT IMMUNORADIOMETRlCASSAY FREE PROSTATE SPECIFIC ANTIGEN UNTUK DETEKSI KANKER PROSTAT

2013 ◽  
Vol 15 (2) ◽  
pp. 14-24
Author(s):  
Puji Widayati ◽  
Gina Mondrida ◽  
Sri Setiyowati ◽  
Agus Ariyanto ◽  
V. Yulianti Susilo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Free Condition ◽  
Free Psa ◽  
Prostate Enlargement ◽  
Assay Design ◽  
Benign Prostate

Prostate Specific Antigen (PSA) is a glycoprotein with a molecular weight of approximately 34,000 daltons serine protease secreted exclusively by prostatic epithelial cells that lining acini and prostate gland. Increased of PSA levels can be caused by prostate cancer or benign prostate enlargement (benign prostatic hyperplasia, BPH). PSA in the blood was found in the free condition (free PSA) and most of the bound protein (complexed-PSA, c-PSA). Measuring levels of PSA was found in the blood can be done by several methods such as by immunoradiometricassay (IRMA) methods or ELISA methods. IRMA method is one of immunoassay techniques using radionuclides ,/' 125 oJ I as a tracer, so the sample in small 13 quantity can be detected The purpose of this study was obtained PSA reagent kit that includes 1251labeled PSA as a tracer, PSA coated tube and PSA standard that requirements of the kit, then it can be optimized assay design, that eventually PSA reagent kit can be used for early detection of prostate cancer. It has been done labeling of Mab PSA using 125 1with reaction time was 90 seconds, amount of PSA MAb was 75 ugram and the activity of Na_ 125I was 1000 flCi. Preaparation of PSA coated tube using 0.05 M Na2C03 solution, at pH: 9.6 with volume was 250 ml., standard PSA with 0.025 Mphosphate buffer at pH 7.4 containing 5% BSA and 0.1% NaN3, and resulting at 1,25% and 14,12% respectively of NSB and BIT that requirement of the kit.Keywords: Prostate cancer, PSA, IRMA,NSB, Maximum Binding

Sign in / Sign up

Export Citation Format

Share Document